292 related articles for article (PubMed ID: 14500349)
1. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion.
Belotti D; Calcagno C; Garofalo A; Caronia D; Riccardi E; Giavazzi R; Taraboletti G
Mol Cancer Res; 2008 Apr; 6(4):525-34. PubMed ID: 18403633
[TBL] [Abstract][Full Text] [Related]
4. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer.
Liu CD; Tilch L; Kwan D; McFadden DW
J Surg Res; 2002 Jan; 102(1):31-4. PubMed ID: 11792148
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of expression of vascular endothelial growth factor and matrix matalloproteinase-2 to invasion of ovarian tumor cells in vitro].
Zhang AL; Wang SX; Lu YP; Li J; Wang CY; Ma D
Ai Zheng; 2002 Mar; 21(3):263-6. PubMed ID: 12451991
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
8. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study of anti-vascular endothelial growth factor hairpin ribozyme gene inhibiting growth of xenografted tumor of ovarian cancer cells].
Yan R; Xin X; Jin M; Hui H; Wang J; Wang D
Zhonghua Fu Chan Ke Za Zhi; 2002 Nov; 37(11):683-6. PubMed ID: 12487926
[TBL] [Abstract][Full Text] [Related]
10. [Effect of irradiation on matrix metalloproteinases, vascular endothelial growth factor and microvessel density of mice bearing Lewis lung cancer].
Ai P; Ren ZG; Wang X; Wang SC; Li P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):632-5. PubMed ID: 19764560
[TBL] [Abstract][Full Text] [Related]
11. The biological effects of antiadhesion agents on activated RAW264.7 macrophages.
Habara T; Nakatsuka M; Konishi H; Asagiri K; Noguchi S; Kudo T
J Biomed Mater Res; 2002 Sep; 61(4):628-33. PubMed ID: 12115453
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells].
Yan RL; Qian XH; Xin XY; Jin M; Hui HX; Wang DT; Wang J
Ai Zheng; 2002 Jan; 21(1):39-44. PubMed ID: 12500395
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
14. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.
Tang Y; Nakada MT; Kesavan P; McCabe F; Millar H; Rafferty P; Bugelski P; Yan L
Cancer Res; 2005 Apr; 65(8):3193-9. PubMed ID: 15833850
[TBL] [Abstract][Full Text] [Related]
16. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
[TBL] [Abstract][Full Text] [Related]
17. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
18. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Zhao Y; Zong ZH; Xu HM
Gynecol Oncol; 2010 Mar; 116(3):563-71. PubMed ID: 20022093
[TBL] [Abstract][Full Text] [Related]
19. [Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer].
Hu ZL; Wen JF; Shen M; Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):70-4. PubMed ID: 16562680
[TBL] [Abstract][Full Text] [Related]
20. The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs.
Liu LP; Liang HF; Chen XP; Zhang WG; Yang SL; Xu T; Ren L
Cancer Invest; 2010 Jun; 28(5):443-51. PubMed ID: 20073580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
